替吉奥联合奥沙利铂治疗晚期结肠癌的临床研究  

Clinical Research of Advanced Colon Carcinoma Patients Treated with S-1 Combinde with Oxaliplatin

作　　者：熊锐华[1] 任庆[1] 田秀荣[1] 唐新云[1] 刘卫明[1] 李桂兰[1] 冯亚琳[1] 

机构地区：[1]中国人民解放军第一八一医院肿瘤治疗中心,桂林541002

出　　处：《中国医药导刊》2012年第7期1208-1210,共3页Chinese Journal of Medicinal Guide

摘　　要：目的:探讨替吉奥联合奥沙利铂在晚期结肠癌化疗中的近期疗效和毒副反应。方法:97例晚期结肠癌患者,随机分为替吉奥+奥沙利铂组(A组)35例,CapeOX组(B组)32例,mFOLFOX6组(C组)30例,三组分别行相应方案化疗。结果:A组CR2例(5.7%),PR17例(48.6%),B组CR1例(3.1%),PR17例(53.1%),C组CR1例(3.3%),PR13例(43.3%),差异无显著意义(P>0.05),A、B组白细胞减少、恶心呕吐较C组少,手足综合征较C组多,差异有显著意义(P<0.05),而A、B组之间则差异无显著意义(P>0.05);三组在血小板减少、血红蛋白降低、腹泻、口腔炎、肝肾功能损害、周围神经炎等方面差异均无统计学意义(P>0.05)。结论:替吉奥联合奥沙利铂在晚期结肠癌化疗中疗效确切,毒副反应低,临床应用方便,有临床应用价值。Objective：To evaluate the efficacy and side effects of the combination of S-1 and OXA in the treatment of patients with adnanced colon carcinoma.Methods：：97 patients adnanced colon carcinoma were randomized into 3 groups：35 cases in the grouop A（S-1 plus OXA）,32 cases in the grouop B（CapeOX） and 30 cases in the grouop C（mFOLFOX6）,then received different chemotherapy respectively.Results：In group A,CR was 2 cases（5.7%）,PR was 17 cases（48.6%）,in group B,CR was 1 case（3.1%）,PR was 17 cases（53.1%）,and in group C,CR was 1 case（3.3%）,PR was 13 cases（43.3%）,there was no significant difference amang the 3 groups（P〉0.05）.In group and group B had lower rate of leucocytopenia and nausea and vomiting but higher rate of hand-foot syndrome than in group C,with a significant difference（P0.05）.The side effects of thrombocytopenia、anaemia、diarrhea、apthous stomatitis、hepatic and renal function and peripheral neuritis had no significant difference amang the 3 groups（P〉0.05）.Conclusion：The regimen of S-1 and OXA is effective on treatment of patients with advanced colon carcinoma and the toxicity is mild,and is easy for clinical application.

关 键 词：结肠癌 替吉奥 奥沙利铂 化学治疗 

分 类 号：R735.35[医药卫生—肿瘤]